CohBar, Inc. Overview
Pro stress-test →CohBar, Inc. was a clinical-stage biotechnology company headquartered in Menlo Park, California that developed mitochondria-based therapeutics targeting chronic and age-related diseases. The company pioneered the exploration of mitochondrial genome-encoded peptides as a novel therapeutic approach, discovering over 100 mitochondrial-derived peptides and generating 1,000+ analogs. The company is no longer operating as of 2023 following a merger with Morphogenesis.
Strategic Profile
Pro stress-test →CohBar held a differentiated position as the first company to mine the mitochondrial genome for therapeutically relevant peptides, establishing a robust IP portfolio. The company's lead candidate, CB4211, was in Phase 1b clinical trials for NASH and obesity. The merger with Morphogenesis shifted focus from mitochondrial therapeutics to personalized cancer vaccines and tumor microenvironment modulators under the new TuHURA Biosciences entity.
Competitive Landscape
Pro stress-test →In its pre-merger period, CohBar competed in the mitochondrial therapeutics and age-related disease treatment space against broader biotech companies developing metabolic and liver disease therapies. Post-merger, the combined entity focused on competing in the personalized cancer vaccine market against established immunotherapy platforms.
Industry Context
CohBar, Inc. operates in Biotechnology - Mitochondrial Therapeutics / Immuno-Oncology (post-merger).
Key facts
Founded: 2007 · Headquarters: Menlo Park, US · Employees: 11 · Revenue: N/A · Market cap: N/A